ZA200705059B - Cancer treatment method - Google Patents

Cancer treatment method

Info

Publication number: ZA200705059B
Authority: ZA; South Africa
Prior art keywords: treatment method; cancer treatment; cancer; treatment
Prior art date: 2004-12-17

Application number

ZA200705059A

Other languages

English (en)

Inventor

Rubin Stephen

Original Assignee

Smith Kline Beecham Cork Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-17

Filing date

2007-06-11

Publication date

2009-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200705059(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-11 Application filed by Smith Kline Beecham Cork Ltd filed Critical Smith Kline Beecham Cork Ltd

2009-09-30 Publication of ZA200705059B publication Critical patent/ZA200705059B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200705059A 2004-12-17 2007-06-11 Cancer treatment method ZA200705059B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US63705204P	2004-12-17	2004-12-17

Publications (1)

Publication Number	Publication Date
ZA200705059B true ZA200705059B (en)	2009-09-30

Family

ID=36588668

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200705059A ZA200705059B (en)	2004-12-17	2007-06-11	Cancer treatment method

Country Status (14)

Country	Link
US (2)	US20080306097A1 (fr)
EP (1)	EP1824492B1 (fr)
JP (1)	JP5291345B2 (fr)
KR (1)	KR20070107004A (fr)
CN (1)	CN101083995A (fr)
AU (1)	AU2005316238B2 (fr)
ES (1)	ES2426007T3 (fr)
IL (1)	IL183059A0 (fr)
MX (1)	MX2007006043A (fr)
NO (1)	NO20072631L (fr)
NZ (1)	NZ555462A (fr)
RU (1)	RU2007119432A (fr)
WO (1)	WO2006066267A2 (fr)
ZA (1)	ZA200705059B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7810677B2 (en)	2004-12-04	2010-10-12	Medical Instill Technologies, Inc.	One-way valve and apparatus and method of using the valve
EP1906185A1 (fr) *	2006-09-26	2008-04-02	ProteoSys AG	Utilisation d'au moins un isoforme de composant 1 récepteur membranaire de la progestérone (PGRMC1)
WO2009137714A2 (fr)	2008-05-07	2009-11-12	Teva Pharmaceutical Industries Ltd.	Formes de ditosylate de lapatinib et procédés pour leur préparation
EP2158912A1 (fr)	2008-08-25	2010-03-03	Ratiopharm GmbH	Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (fr)	2008-08-25	2010-03-03	Ratiopharm GmbH	Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
CN102421427B (zh)	2009-03-11	2013-11-06	阿迪生物科学公司	用于治疗特定癌症的包含rdea119/bay869766的药物组合
CN102146075B (zh) *	2010-02-06	2014-04-02	浙江九洲药业股份有限公司	一种喹唑啉化合物的制备方法
US8710221B2 (en)	2010-03-23	2014-04-29	Scinopharm Taiwan, Ltd.	Process and intermediates for preparing lapatinib
CA2793742C (fr)	2010-03-23	2015-06-23	Scinopharm Taiwan Ltd.	Procede et intermediaires pour la preparation du lapatinib
CN102344445B (zh) *	2010-07-23	2015-11-25	岑均达	光学纯喹唑啉类化合物
CN102344444B (zh) *	2010-07-23	2015-07-01	岑均达	光学纯喹唑啉类化合物
CN102321076B (zh) *	2011-07-07	2013-08-21	中国科学技术大学	拉帕替尼中间体及其类似物的制备方法
CZ2012712A3 (cs)	2012-10-17	2014-04-30	Zentiva, K.S.	Nový způsob výroby klíčového intermediátu výroby lapatinibu
CN106632276B (zh) *	2015-10-28	2021-06-15	上海天慈生物谷生物工程有限公司	一种治疗乳腺癌药物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9800569D0 (en) *	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
DE60203260T2 (de) *	2001-01-16	2006-02-02	Glaxo Group Ltd., Greenford	Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
CA2569139A1 (fr) *	2004-06-04	2005-12-22	Smithkline Beecham (Cork) Limited	Lapatinib et letrozole pour utilisation dans le traitement du cancer du sein

2005
- 2005-12-16 AU AU2005316238A patent/AU2005316238B2/en not_active Ceased
- 2005-12-16 KR KR1020077016268A patent/KR20070107004A/ko not_active Withdrawn
- 2005-12-16 ES ES05854982T patent/ES2426007T3/es not_active Expired - Lifetime
- 2005-12-16 MX MX2007006043A patent/MX2007006043A/es not_active Application Discontinuation
- 2005-12-16 RU RU2007119432/14A patent/RU2007119432A/ru not_active Application Discontinuation
- 2005-12-16 EP EP05854982.5A patent/EP1824492B1/fr not_active Expired - Lifetime
- 2005-12-16 NZ NZ555462A patent/NZ555462A/en not_active IP Right Cessation
- 2005-12-16 WO PCT/US2005/046350 patent/WO2006066267A2/fr not_active Ceased
- 2005-12-16 JP JP2007547043A patent/JP5291345B2/ja not_active Expired - Fee Related
- 2005-12-16 CN CNA2005800434300A patent/CN101083995A/zh active Pending
- 2005-12-16 US US11/721,675 patent/US20080306097A1/en not_active Abandoned
2007
- 2007-05-08 IL IL183059A patent/IL183059A0/en unknown
- 2007-05-22 NO NO20072631A patent/NO20072631L/no not_active Application Discontinuation
- 2007-06-11 ZA ZA200705059A patent/ZA200705059B/xx unknown
2015
- 2015-04-20 US US14/690,917 patent/US20150283139A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2006066267A3 (fr)	2006-12-14
EP1824492A2 (fr)	2007-08-29
EP1824492A4 (fr)	2009-10-28
AU2005316238A1 (en)	2006-06-22
MX2007006043A (es)	2007-06-13
JP5291345B2 (ja)	2013-09-18
AU2005316238B2 (en)	2009-05-07
NZ555462A (en)	2009-03-31
EP1824492B1 (fr)	2013-07-10
NO20072631L (no)	2007-07-02
US20080306097A1 (en)	2008-12-11
US20150283139A1 (en)	2015-10-08
KR20070107004A (ko)	2007-11-06
JP2008524258A (ja)	2008-07-10
ES2426007T3 (es)	2013-10-18
IL183059A0 (en)	2007-10-31
CN101083995A (zh)	2007-12-05
WO2006066267A2 (fr)	2006-06-22
RU2007119432A (ru)	2009-01-27

Publication	Publication Date	Title
ZA200705059B (en)	2009-09-30	Cancer treatment method
IL183889A0 (en)	2007-10-31	Treatment method
EP1814544A4 (fr)	2009-12-02	Traitements anti-cancereux
EP1755394A4 (fr)	2009-08-05	Methode de traitement du cancer
PT1830847E (pt)	2015-02-05	Tratamento para o cancro
IL178920A0 (en)	2007-03-08	Treatment for pancreatic cancer
EP1909854A4 (fr)	2012-02-22	Procédé pour traiter le cancer
GB0428187D0 (en)	2005-01-26	Cancer treatment
IL179323A0 (en)	2007-05-15	Cancer treatment method
EP2088862A4 (fr)	2009-12-02	Méthode de traitement du cancer
ZA200607115B (en)	2007-09-26	Permanent treatment method
GB0413346D0 (en)	2004-07-21	Treating cancer
IL179359A0 (en)	2007-03-08	Cancer treatment method
GB2430002B (en)	2009-06-03	Well treatment
EP1809276A4 (fr)	2009-06-17	Procede de traitement
EP1802617A4 (fr)	2010-12-15	Méthode de traitement du cancer
GB0424085D0 (en)	2004-12-01	Well treatment
GB0426141D0 (en)	2004-12-29	Treatment
GB0404675D0 (en)	2004-04-07	Cancer treatment
GB0407354D0 (en)	2004-05-05	Treatment apparatus
GB0507685D0 (en)	2005-05-25	Cancer treatment
GB0423273D0 (en)	2004-11-24	Treatment of cancer
HK1104284A (en)	2008-01-11	Cancer treatment method
HK1103980A (en)	2008-01-04	Cancer treatment method
HK1107260A (en)	2008-04-03	Cancer treatment method